• ADC Therapeutics SA is preparing to announce quarterly earnings with an expected EPS of -$0.39 and projected revenue of $19 million.
• The company will host a conference call and live webcast to provide operational updates and discuss financial results.
• Current financial metrics display a solid current ratio of 4.92, but concerns linger regarding profitability and debt levels.

ADC Therapeutics SA, traded on the NYSE as ADCT, is recognized for its advancement in antibody drug conjugates, crucial cancer-targeting therapies. On March 27, 2025, ADC is set to release its quarterly earnings, with Wall Street estimating an EPS of -$0.39 alongside projected revenue of $19 million.

The day of the earnings report, ADCT will host a conference call and live webcast at 8:30 a.m. EDT to discuss its financial results for the fourth quarter and year ending December 31, 2024. Participants can access the event via a toll-free number for North America and Canada, with web access via the company’s website.

Financial metrics for ADCT tell a mixed story. The company has a price-to-sales ratio of 2.21 and an enterprise value to sales ratio of 3.02, key indicators for market valuation. However, its negative price-to-earnings ratio of -0.80 and earnings yield of -1.25% reflect current profitability issues.

Despite these challenges, ADCT’s strong current ratio of 4.92 signals a robust ability to meet short-term liabilities. Nonetheless, an enterprise value to operating cash flow ratio of -1.60 combined with a concerning debt-to-equity ratio of -1.93 raises alarms for investors about the company’s debt levels.